The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Very tame sng snippet in the telegraph today. Plenty on treatments that don’t work.
Another way of boosting immunity is to give synthetic interferons, which boost the immune system while also keeping it in check. Last year, British pharma company Synairgen published results showing interferon “SNG001” lowered the risk of severe Covid-19.
Interferons SNG001, an inhaled form of interferon, has been shown to lower the risk of severe Covid in infected cases. Studies are ongoing.
Market expected the RNS so price was alredy built in. Now seeing the usual fall back . Could drop to low 70’s which was the price at and around 5th Feb.
I suspect lots are jumping ship over to odx.
So far today it’s a net sell. Surprised there is no interest at this price. Perhaps it could fall lower. The spread is often much narrower than that quoted.
Need to switch on ‘after hours quote’ to see pdsb price of 5.990
So much for the 10:1 consolidation reducing volatility.
The RNS states government wants 2 mil left per day and omega states with loan kit it will produce 2 mil per week. Then omega states it expects this capacity will meet the demands for lfts. But government wants 2 mil per day.
It’s tanking with lots of profit taking.
Looks like pump and dump?
“ Hi, anyone know the reason for the sudden rapid rise in price?
Thanks.”
Yes: it’s reached a support level and will move up to a resistance. Traders make shed loads of money off these ‘predictable’ oscillations.
Been reluctant to go above the 65p placing in Aug 2020. I wonder if nsci will decide to temporarily suspend the shares again?
British firm readies launch of AI-powered rapid Covid test
Two British companies have joined forces to develop a rapid Covid test that they claim will be the most sensitive in the world when it launches in March, Julia Bradshaw reports.
The lateral flow test was developed by Excalibur Healthcare Services, a Cambridge-based diagnostics company founded and led by biotech entrepreneur Sir Chris Evans. Embedded in the test is artificial intelligence software from medical technology company Sensyne Health.
If a lateral flow test is positive, a red line appears on the result window. The stronger the line, the higher the viral load. "Some people light up like a Christmas tree," Sir Chris said.
This new test is ultra-sensitive and can detect in less than 10 minutes extremely low levels of the Covid virus in the body.
"I am confident this is the best test in the world," said Sir Chris. "No one has ever had a lateral flow test get the level we have and it is a combination of that brilliant algorithm software and our sensitive reagents."
Pdsb showing huge volume, nsci piddling little interest. Could do with a RNS from nsci to wake the world up.
I find the spread is often not as wide as stated. Suggest get a buy quote and you may be pleasantly surprised
Mologic now in partnership with avacta. Thought Mologic were going to be the main supplier to omega?
Today we announced a partnership with @Avacta to accelerate to market its AffiDX™ #SARSCoV2 #lateralflow rapid antigen test. The partnership will enable faster #CEmarking for professional use and additional manufacturing capacity. For more info, visit: bit.ly/3q4miBI
Reuters) - British drugmaker AstraZeneca (L:AZN) said on Saturday its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of COVID-19, based on early data from a trial.
The study from South Africa's University of the Witwatersrand and Oxford University showed the vaccine had significantly reduced efficacy against the South African variant, according to a Financial Times report published earlier in the day.
Among coronavirus variants currently most concerning for scientists and public health experts are the so-called British, South African and Brazilian variants, which appear to spread more swiftly than others.
"In this small phase I/II trial, early data has shown limited efficacy against mild disease primarily due to the B.1.351 South African variant," an AstraZeneca spokesman said in response to the FT report.
The newspaper said none of the more than 2,000 trial participants had been hospitalised or died.
"However, we have not been able to properly ascertain its effect against severe disease and hospitalisation given that subjects were predominantly young healthy adults," the AstraZeneca spokesman said.
The company said it believed its vaccine could protect against severe disease, given that the neutralising antibody activity was equivalent to that of other COVID-19 vaccines that have demonstrated protection against severe disease.
The trial, which involved 2,026 people of whom half formed the placebo group, has not been peer-reviewed, the FT said.
While thousands of individual changes have arisen as the virus mutates into new variants, only a tiny minority are likely to be important or change the virus in an appreciable way, according to the British Medical Journal.
"Oxford University and AstraZeneca have started adapting the vaccine against this variant and will advance rapidly through clinical development so that it is ready for Autumn delivery should it be needed," the AstraZeneca spokesman said.
On Friday Oxford said their vaccine has similar efficacy against the British coronavirus variant as it does to the previously circulating variants.
LONDON (Reuters) - British drugmaker AstraZeneca (NASDAQ:AZN) said on Saturday it believed its COVID-19 vaccine developed with the University of Oxford could protect against severe disease caused by the South African variant of the virus.
AstraZeneca confirmed that early data from a small trial, first reported by the Financial Times, had shown limited efficacy for the vaccine against mild disease primarily due to this variant.
"We do believe our vaccine could protect against severe disease, as neutralising antibody activity is equivalent to that of other COVID-19 vaccines that have demonstrated activity against more severe disease, particularly when the dosing interval is optimised to 8-12 weeks," a spokesman said in a statement.
Recent FT report:
The Oxford/AstraZeneca Covid-19 vaccine does not appear to offer protection against mild and moderate disease caused by the viral variant first identified in South Africa, according to a study due to be published on Monday.
“
Given the proportionate spike in August I'm surprised this isn't higher. I hold PDSB and am happy but NSCI doesn't really equate now to what happened back then. We shall see.”
It’s all a game. Mm sent the sp up on a spike to get us gullible folk to worry we are missing out. Then it comes down again and over time lots of folk cut their losses and the mm make the money.
“
Guys, surely you agree the SP should be way higher than it is based on all the information we read and hear week on week ?”
If I had a pound for every time I hear this I wouldn’t need to invest in shares.